Patients who have signed written informed consent

Adult patients ≥ 18 years

Oligometastatic hormone sensitive prostate cancer defined as presence of ≤ 5 non-visceral metastatic lesions \*, \*\*

All lesions must be amenable to SBRT in judgment of treating radiation oncologist \*\*\*

Patients with metastatic recurrence after previous radical prostatectomy or definitive radiotherapy will be included in the trial, provided that radical approach on prostate is administered

Androgen deprivation therapy (ADT) started ≤ 6 months before enrollment

Patients should be eligible to Apalutamide treatment

Minimum age: 18

Presence of visceral disease

De novo metastatic disease

Any contraindication to the use of Apalutamide

Any condition for which, in the opinion of the treating physician, SBRT should not be proposed or could be contraindicated